is true for the other reported cases, the primary identification of the Saccharomyces species was incorrect, with the usual confusion As a pharmaceutical biotherapeutic agent, Saccharomyces boulbetween S. boulardii and S. cerevisiae [1, 2, 5] . ardii has been used for years outside of the United States to treat Given that S. boulardii may be initially misidentified as S. cerediarrhea [1] and is considered to be safe. Nevertheless, serious visiae, it is likely that S. boulardii is responsible for saccharomyces side effects can occur. fungemia in patients receiving enteral Ultra-Levure. High doses A 78-year-old immunocompetent woman was admitted to the of Ultra-Levure associated with antibiotics effective against anaerintensive care unit because of an acute exacerbation of chronic obes, bowel diseases, and/or immunodeficiency seem to be risk obstructive pulmonary disease. Current treatment consisted of antifactors for such fungemia; our observation suggests that fungemia biotics (amoxicillin/clavulanic acid), mechanical ventilation, and due to Saccharomyces species can also occur in immunocompetent enteral feeding via a gastric tube. On hospital day 12, diarrhea hosts without bowel disease. Enteral S. boulardii is widely used appeared. Investigation for stool pathogens was negative; loperain the prevention or treatment of diarrhea; therefore, physicians mide and S. boulardii (Ultra-Levure, 1.5 g/day [Biocodex, Monmust be aware of the possibility of potentially serious side effects. trouge, France]) were administered via the gastric tube (day 13)
The reported occurrence of such side effects is infrequent at presfor 15 days. On day 18, antibiotic therapy was changed to that with ent, and no current guidelines exist for their treatment. ceftazidime and ciprofloxacin because of a nosocomial pulmonary infection. On day 34, the temperature was elevated to 39ЊC and M. charomyces species from an affected bowel (e.g., ischemic or in- (e.g., patients with AIDS and patients receiving corticosteroid therSaccharomyces fungemia in AIDS patients after treatment for chronic apy) [3] [4] [5] [6] [7] [8] . In all reported cases, therapy has consisted of support- 
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CSF and plasma viral loads remained undetectable.
To improve the quality of life for our patient, we decided to Foscarnet, a reverse transcriptase inhibitor, has been shown to interrupt foscarnet administration without modifying the rest of decrease HIV-1 replication in vitro [1, 2] . Recently, reports of two the treatment. A lumbar puncture performed 2 weeks later showed studies about the effects of this antiviral agent on HIV replication a detectable HIV RNA viral load at 3 log 10 copies/mL. A third in vivo were published [3, 4] . Both investigators observed signifiepisode of mental dysfunction, associated with an important rise cant reductions of HIV plasma viral loads in patients who were in CSF viral load (5.1 log 10 RNA HIV copies/mL), occurred 6 treated with foscarnet. Herein, we report an observation that foscarweeks after stopping foscarnet. Therapy was switched to that with net is also active in the CNS when used to treat HIV encephalonew drugs available at this time, abacavir, nevirapine, and nelfipathy-related symptoms. navir, with successful clinical and virological response. A 55-year-old HIV-1-infected man with a Burkitt's lymphoma Foscarnet has been shown to penetrate the blood-brain barrier was treated with indinavir (800 mg t.i.d.) and saquinavir (400 mg [5] . In our patient, foscarnet was highly effective in reducing the b.i.d.). Therapy with this combination of two protease inhibitors CSF HIV viral load and neurological symptoms, and this effect was started during multidrug chemotherapy for his lymphoma to was sustained throughout the 3 months of therapy. The CSF HIV avoid myelotoxicity induced by nucleoside analogs. Since the RNA load rebounded 2 weeks after cessation of therapy, and cliniplatelet count remained low (30,000/mm 3 ) and plasma HIV viral cal symptoms reappeared a few weeks later. load was undetectable, antiretroviral therapy was not modified after
The CNS is a protected compartment, known to be difficult to completion of the antineoplastic treatment, which led to complete reach, since antiretroviral drugs like protease inhibitors do not remission. The CD4/ cell count was 150/mm 3 . cross the blood-brain barrier efficiently. This phenomenon is illusThe patient works as a translator. Six months after beginning trated in the case we described, given the occurrence of neurologitherapy with protease inhibitors, he experienced a first episode of cal symptoms associated with a high CSF viral load despite undesomnolence, lack of concentration, and inability to work. Brain tectable HIV RNA in plasma. In our patient, clinical evolution CT scan and MRI showed no abnormalities. A CSF specimen paralleled changes in CSF HIV RNA, indicating that high CSF contained 3 lymphocytes/mm 3 and protein levels were normal. viral loads can be a marker of HIV encephalopathy. Our observaMicroscopic examination and cultures of CSF were negative for tion suggests that foscarnet might be helpful for the treatment bacteria, parasites, and fungi. A search for neoplastic cells and of HIV-associated mental deterioration in cases of resistance or cryptococcal antigen was negative. A PCR assay of CSF was intolerance to all antiretroviral drugs known to be active in negative for herpes simplex virus types 1 and 2, cytomegalovirus the CNS. (CMV), JC virus, and Toxoplasma gondii. The CSF HIV viral load was 4.23 log 10 HIV RNA copies/mL, whereas the plasma viral Marie-Luce Delforge, Claire-Michèle Farber, load was still undetectable. Zidovudine at low doses (100 mg t.i.d.)
Frédéric De Leener, Jean-Marc Caroyer, was added to the treatment. After 2 weeks, the patient regained Corinne Liesnard, and Jean-Paul Van Vooren his fluency in six languages, and CSF HIV viral load levels de- 
